Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BioPheresis logo — Discover the future of cancer treatment with our innovative...

BioPheresis

Discover the future of cancer treatment with our innovative blood purification technology that targets and removes cancer-protecting immune-inhibitors.

Founded 2003 2-10 employees Series A Total: $8.00M Biotechnology, Health Care

General Information

Company Name BioPheresis
Founded Year 2003
Employees 2-10
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with BioPheresis. To contact BioPheresis, visit biopheresis.de.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About BioPheresis

BioPheresis, a biotechnology startup, offers a groundbreaking blood purification technology for cancer treatment. The company, founded in 2003 and operating through its subsidiary BioPheresis GmbH in Heidelberg, Germany, has developed a patent-protected system to eliminate specific cancer-protecting immune-inhibitors from the bloodstream. Its recent $8.00M Series A investment on 13 May 2005 was led by firstVentury Equity and SLS Venture. With a focus on the biotechnology and healthcare industries, BioPheresis is poised to revolutionize cancer treatment with its innovative approach to blood purification.

Taxonomy: Cancer treatment, Blood purification, Immune-inhibitors, BioPheresis Technologies, Innovative technology, Patent-protected system, Medical technology, Healthcare innovation, Research and development, Biomedical engineering, Oncology, Immunotherapy, Medical devices, Clinical trials

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $8.00M 2
firstVentury Equity, SLS Venture
13 May 2005

BioPheresis Alternatives & Competitors

View All Alternatives
BioPheresis vs
NKure Therapeutics
NKure Therapeutics India

Creating affordable anticancer immunotherapies with natural killer (NK) cells

Seed
10 employees
Biotechnology, Health Care
BioPheresis vs
Juventas Cell Therapy Corp.
Juventas Cell Therapy Corp. China

合源生物科技（天津）有限公司创立于2018年6月，是一家专注于免疫细胞治疗等创新型药物研发和商业化的生物...

Series C
32 employees
Biotechnology, Health Care
BioPheresis vs
ViraTherapeutics GmbH
ViraTherapeutics GmbH Austria

We make cancer immunotherapies more powerful.

Series A
31 employees
Biotechnology, Health Care
View all alternatives

FAQ About BioPheresis

Discover the future of cancer treatment with our innovative blood purification technology that targets and removes cancer-protecting immune-inhibitors.
BioPheresis was founded in 2003.
BioPheresis operates in Biotechnology and Health Care. Its work centres on Cancer treatment, Blood purification, Immune-inhibitors and BioPheresis Technologies.
BioPheresis has approximately 2-10 employees.
BioPheresis has completed 1 funding round, raising a total of $8.00M. The latest funding stage is Series A.
Top alternatives and competitors to BioPheresis include NKure Therapeutics, Juventas Cell Therapy Corp., ViraTherapeutics GmbH, Phoenix Molecular Designs, ImmunOs Therapeutics AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioPheresis and NKure Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioPheresis, https://bouncewatch.com/company/biopheresis, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes